149 related articles for article (PubMed ID: 3306667)
1. High sensitivity and specificity of CA 19-9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings.
Safi F; Roscher R; Bittner R; Schenkluhn B; Dopfer HP; Beger HG
Pancreas; 1987; 2(4):398-403. PubMed ID: 3306667
[TBL] [Abstract][Full Text] [Related]
2. CA 19-9 and pancreatic adenocarcinoma.
Safi F; Beger HG; Bittner R; Büchler M; Krautzberger W
Cancer; 1986 Feb; 57(4):779-83. PubMed ID: 3455839
[TBL] [Abstract][Full Text] [Related]
3. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9.
Safi F; Roscher R; Beger HG
Hepatogastroenterology; 1989 Dec; 36(6):419-23. PubMed ID: 2613165
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic importance of the tumor marker CA 19-9 in pancreatic cancer].
Safi F; Büchler M; Schenkluhn B; Beger HG
Dtsch Med Wochenschr; 1984 Dec; 109(49):1869-73. PubMed ID: 6209082
[TBL] [Abstract][Full Text] [Related]
5. The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma.
Safi F; Roscher R; Beger HG
Bull Cancer; 1990; 77(1):83-91. PubMed ID: 2180502
[TBL] [Abstract][Full Text] [Related]
6. CA 242 is a new tumor marker for pancreatic cancer.
Röthlin MA; Joller H; Largiadèr F
Cancer; 1993 Feb; 71(3):701-7. PubMed ID: 8431849
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical study of neuron-specific enolase and CA 19-9 in pancreatic disorders. The value of neuron-specific enolase as a marker for islet cell and nerve tissue.
Iwase K; Kato K; Nagasaka A; Miura K; Kawase K; Miyakawa S; Tei T; Ohtani S; Inagaki M; Shinoda S
Gastroenterology; 1986 Sep; 91(3):576-80. PubMed ID: 3015709
[TBL] [Abstract][Full Text] [Related]
8. [Ca 19-9 antigen in differentiation of pancreatic inflammatory and neoplastic tumors].
Markocka-Maczka K
Wiad Lek; 2003; 56(11-12):537-40. PubMed ID: 15058160
[TBL] [Abstract][Full Text] [Related]
9. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis.
Malesci A; Tommasini MA; Bonato C; Bocchia P; Bersani M; Zerbi A; Beretta E; Di Carlo V
Gastroenterology; 1987 Jan; 92(1):60-7. PubMed ID: 3465666
[TBL] [Abstract][Full Text] [Related]
10. Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9.
Haglund C; Lindgren J; Roberts PJ; Kuusela P; Nordling S
Br J Cancer; 1989 Dec; 60(6):845-51. PubMed ID: 2557879
[TBL] [Abstract][Full Text] [Related]
11. Comparative study on the expression of the blood group antigens Le a, Le b, Le x, Le y and the carbohydrate antigens CA 19-9 and CA-50 in chronic pancreatitis and pancreatic carcinoma.
Schwenk J; Makovitzky J
Virchows Arch A Pathol Anat Histopathol; 1989; 414(6):465-76. PubMed ID: 2499104
[TBL] [Abstract][Full Text] [Related]
12. DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease.
Mahvi DM; Seigler HF; Meyers WC; Kalthoff H; Schmiegel WH; Metzgar RS
Pancreas; 1988; 3(4):488-93. PubMed ID: 3174610
[TBL] [Abstract][Full Text] [Related]
13. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
Blind PJ; Dahlgren ST
Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
[TBL] [Abstract][Full Text] [Related]
16. The distribution and localization of the monoclonal antibody-defined antigen 19-9 (CA19-9) in chronic pancreatitis and pancreatic carcinoma. An immunohistochemical study.
Makovitzky J
Virchows Arch B Cell Pathol Incl Mol Pathol; 1986; 51(6):535-44. PubMed ID: 2878526
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S
Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
[TBL] [Abstract][Full Text] [Related]
19. [Value of plasma testosterone, carcinoembryonic antigen and CA 19-9 in the differential diagnosis of pancreatic carcinoma and chronic pancreatitis].
Jurkowska G; Kulpa J; Skrodzka D; Rogowski F
Pol Arch Med Wewn; 1992 Nov; 88(5):302-9. PubMed ID: 1300550
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of carbohydrate antigens 19-9 and 12-5 in patients with pancreatic cancer.
Pasquali C; Sperti C; D'Andrea AA; Bonadimani B; Del Favero G; Petrin P; Pedrazzoli S
Pancreas; 1987; 2(1):34-7. PubMed ID: 3472197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
